The Chefs' Warehouse, Inc. (CHEF)
NASDAQ: CHEF · Real-Time Price · USD
62.38
+0.08 (0.13%)
Aug 12, 2025, 11:34 AM - Market open
Orchard Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Orchard Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $69.33, which forecasts a 11.14% increase in the stock price over the next year. The lowest target is $58 and the highest is $79.
Price Target: $69.33 (+11.14%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Orchard Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy Maintains $68 → $79 | Strong Buy | Maintains | $68 → $79 | +26.64% | Jul 31, 2025 |
| UBS | UBS | Strong Buy Maintains $72 → $78 | Strong Buy | Maintains | $72 → $78 | +25.04% | Jul 31, 2025 |
| UBS | UBS | Strong Buy Maintains $68 → $72 | Strong Buy | Maintains | $68 → $72 | +15.42% | Jul 28, 2025 |
| UBS | UBS | Strong Buy Maintains $67 → $68 | Strong Buy | Maintains | $67 → $68 | +9.01% | May 1, 2025 |
| Benchmark | Benchmark | Strong Buy Reiterates $68 | Strong Buy | Reiterates | $68 | +9.01% | Mar 17, 2025 |
Financial Forecast
Revenue This Year
4.12B
from 3.79B
Increased by 8.64%
Revenue Next Year
4.26B
from 4.12B
Increased by 3.28%
EPS This Year
1.75
from 1.32
Increased by 32.26%
EPS Next Year
2.07
from 1.75
Increased by 18.57%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 4.3B | 4.6B | 5.0B | |
| Avg | 4.1B | 4.3B | 4.8B | |
| Low | 3.9B | 3.2B | 4.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 12.3% | 11.8% | 16.9% | |
| Avg | 8.6% | 3.3% | 13.5% | |
| Low | 3.9% | -22.1% | 9.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 1.94 | 2.26 | 2.49 | |
| Avg | 1.75 | 2.07 | 2.38 | |
| Low | 1.59 | 1.84 | 2.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 47.1% | 29.3% | 20.2% | |
| Avg | 32.3% | 18.6% | 15.0% | |
| Low | 20.2% | 5.5% | 8.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.